logo

For the Inventor, By the Inventor

Macquarie Park, Australia

Teva Pharmaceuticals Australia Pty Ltd

Calculating rank
USPTO Granted Patents = 14

% Expired Patents = 14.3



Forward Citations = 37

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Anthony Gerard Doyle (11 out of 32 patents)

silverMedal Adam Clarke (8 out of 25 patents)

bronzeMedal Matthew Pollard (8 out of 21 patents)

4.  Sarah Lee Pogue (8 out of 18 patents)

5.  Tetsuya Taura (7 out of 7 patents)

6.  Collette Behrens (6 out of 7 patents)

7.  David S Wilson, Jr (5 out of 8 patents)

8.  David S Wilson (4 out of 6 patents)

9.  Wouter Korver (2 out of 13 patents)

10.  Teresa Domagala (2 out of 2 patents)

11.  Tetsuo Yamagishi (2 out of 2 patents)

12.  Stephen Tran (2 out of 3 patents)

13.  Jack Tzu Chiao Lin (2 out of 2 patents)

14.  Philip Anthony Jennings (2 out of 8 patents)

15.  Norbert A Kienzle (2 out of 3 patents)


14 patents:

1. 12258401 - Anti-CD47 combination therapy (2025-03-25),
2. 11618784 - Anti-CD47 combination therapy (2023-04-04),
3. 11319356 - Interferon alpha 2B variants (2022-05-03),
4. 11253591 - Combination of lenalidomide and polypeptide construct, and uses thereof (2022-02-22),
5. 11117975 - Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B (2021-09-14),
6. 10981986 - Fusions of antibodies to CD38 and attenuated interferon alpha (2021-04-20),
7. 10822422 - Antibodies against TL1a and uses thereof (2020-11-03),
8. 10544199 - Interferon alpha 2B variants (2020-01-28),
9. 9963515 - Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B (2018-05-08),
10. 9636334 - Combination of lenalidomide and polypeptide construct, and uses thereof (2017-05-02),
11. 9611322 - Fusions of antibodies to CD38 and attenuated interferon alpha (2017-04-04),
12. 9505826 - Modified antibody with improved half-life (2016-11-29),
13. 8932588 - Treatment of cancer involving mutated KRAS or BRAF genes (2015-01-13),
14. 8901279 - Humanized antibodies with anti-tumor activity (2014-12-02),
Company Overview
Teva Pharmaceuticals Australia Pty Ltd is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of generic and specialty medications. The company is dedicated to providing high-quality, accessible healthcare solutions across various therapeutic areas, including pain management, respiratory, and central nervous system disorders. With a commitment to innovation, Teva leverages advanced research and technology to enhance patient outcomes and address unmet medical needs in Australia and beyond.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#4 in Macquarie Park

#271 in Australia

#42,290 in the World

Macquarie Park, AU
Macquarie Park, Australia

Teva Pharmaceuticals Australia Pty Ltd

Forward Citations = 37

21 inventors:

goldMedal Anthony Gerard Doyle (11 out of 32 patents)

silverMedal Adam Clarke (8 out of 25 patents)

bronzeMedal Matthew Pollard (8 out of 21 patents)

4.  Sarah Lee Pogue (8 out of 18 patents)

5.  Tetsuya Taura (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Teva Pharmaceuticals Australia Pty Ltd. Retrieved from https://idiyas.com/company/teva-pharmaceuticals-australia-pty

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…